Platelet Activation and Aggregation Induced by Recombinant von Willebrand Factors Reproducing Four Type 2B von Willebrand Disease Missense Mutations

Summary

Type 2B of von Willebrand disease (vWD) refers to qualitative variants with increased affinity of von Willebrand factor (vWF) for platelet glycoprotein Ib (GPIb). All the mutations responsible for type 2B vWD have been located in the A1 domain of vWF. In this study, various recombinant von Willebrand factors (rvWF) reproducing four type 2B vWD missense mutations were compared to wild-type rvWF (WT-rvWF) for their spontaneous binding to platelets and their capacity to induce platelet activation and aggregation. Our data show that the multimeric pattern of each mutated rvWF is similar to that of WT-rvWF but the extent of spontaneous binding and the capacity to induce platelet activation and aggregation are more important for the R543Q and V553M mutations than for the L697V and A698V mutations. Both the binding of mutated rvWFs to platelets and platelet aggregation induced by type 2B rvWFs are inhibited by monoclonal anti-GPIb and anti-vWF antibodies, inhibitors of vWF binding to platelets in the presence of ristocetin, as well as by aurin tricarboxylic acid. On the other hand, EDTA and a monoclonal antibody directed against GPIIb/IIIa only inhibit platelet aggregation. Furthermore, the incubation of type 2B rvWFs with platelets, under stirring conditions, results in the decrease in high molecular weight vWF multimers in solution, the extent of which appears correlated with that of plasma vWF from type 2B vWD patients harboring the corresponding missense mutation. This study supports that the binding of different mutated type 2B vWFs onto platelet GPIb induces various degrees of platelet activation and aggregation and thus suggests that the phenotypic heterogeneity of type 2B vWD may be related to the nature and/or location of the causative point mutation.

• References

• 1 Ruggeri ZM, Ware J. The structure and function of von Willebrand factor. Thromb Haemost 1992; 67: 594-9.
• 2 Sixma JJ, De Groot PG. Regulation of platelet adhesion to the vessel wall. Ann NY Acad Sci 1994; 714: 190-9.
• 3 Sadler JE. A revised classification of von Willebrand disease. For the subcommittee on von Willebrand factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1994; 71: 520-5.
• 4 Ruggeri ZM, Pareti FI, Mannucci PM, Ciavarella N, Zimmerman TS. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand’s disease. New Engl J Med 1980; 302: 11047-51.
• 5 Murata M, Fukuyama M, Satoh K, Fujimura K, Yoshioka A, Takahashi H, Handa M, Kawai Y, Watanabe K, Ikeda Y. Low shear stress can initiate von Willebrand factor-dependent platelet aggregation in patients with type-IIB and platelet-type von Willebrand disease. J Clin Invest 1993; 92: 1555-8.
• 6 Ginsburg D, Sadler JE. Von Willebrand disease: a database of point mutations, insertions and deletions. Thromb Haemost 1993; 64: 326-32.
• 7 Fujimura Y, Titani K, Holland LZ, Robert JR, Elder JH, Ruggeri ZM, Zimmerman TS. Von Willebrand factor: a reduced and alkylated 52/48 kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. J Biol Chem 1986; 261: 381-5.
• 8 De Romeuf C, Mazurier C. Interest of a simple and fast method for platelet von Willebrand factor characterization. Thromb Res 1996; 83: 287-98.
• 9 Hilbert L, Gaucher C, de Romeuf C, Horellou MH, Vink T, Mazurier C. Leu 697 → Val mutation in mature von Willebrand factor is responsible for type IIB von Willebrand disease. Blood 1994; 83: 1542-50.
• 10 Hilbert L, Gaucher C, and Mazurier C. Effects of different amino-acid substitutions in the Leucine 694-Proline 708 segment of recombinant von Willebrand factor. Br J Haematol 1995; 91: 983-90.
• 11 Hilbert L, Gaucher C, de Romeuf C, Parquet A, Abgrall JF, Trzeciak C, Mazurier C. Identification of “new” type 2B von Willebrand disease mutation: R543Q, R545P and R578L. Br J Haematol. 1996 93 suppl 2: abstract 1175.
• 12 Bonthron D, Orr EC, Mitsock LM, Ginsburg D, Handin RI, Orkin SH. Nucleotide sequence of the pre-pro-von Willebrand factor cDNA. Nucleic Acid Res 1986; 14: 7125-7.
• 13 Mazurier C, Parquet-Gernez A, Goudemand M. Dosage de l’antigène lié au facteur VIII par la technique ELISA. Intérêt dans l’étude de la maladie de Willebrand. Path Biol 1977; 25: 18-24.
• 14 Mazurier C, Samor B, Goudemand M. Improved characterization of plasma von Willebrand factor heterogeneity when using 2.5% agarose gel electrophoresis. Thromb Haemost 1986; 55: 61-4.
• 15 Rabinowitz I, Randi AM, Shindler KS, Tuley EA, Ruatogi PK, and Sadler JE. Type IIB mutation His 505→Asp implicates a new segment in the control of von Willebrand factor binding to platelet glycoprotein Ib. J Biol Chem 1993; 268: 20497-501.
• 16 Gralnick HR, Williams SB, and Morisato DK. Effect of multimeric structure of the factor VIII/vWF protein on binding to platelets. Blood 1981; 58: 387-97.
• 17 Federici AB, Bader R, Pagani S, Colibretti AL, De Marco L, Mannucci PM. Binding of von Willebrand factor (vWF) to glycoproteins (GP) Ib and IIb-IIIa complex: affinity is related to multimeric size. Br J Haematol 1987; 73: 93-9.
• 18 Gralnick HR, Williams SB, Mc Keown LP, Rick ME, Maisonneuve P, Jeanneau C, Sultan Y. Von Willebrand’s disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor. J Clin Invest 1985; 76: 1522-9.
• 19 De Marco L, Girolami A, Zimmerman TS, Ruggeri ZM. Interaction of purified IIB von Willebrand factor with the platelet membrane glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb-IIIa complex and initiates aggregation. Proc Natl Acad Sci 1985; 82: 7424-8.
• 20 De Marco L, Mazzuccato M, Del Ben MG, Budde U, Federici AB, Girolami A, Ruggeri ZM. Type IIB von Willebrand factor with normal sialic acid content induces platelet aggregation in the absence of ristocetin. Role of platelet activation, fibrinogen and two distinct membrane receptors. J Clin Invest 1987; 80: 475-82.
• 21 Ikeda Y, Handa M, Kawano K, Kamata T, Murata M, Araki Y, Anbo H, Kawai Y, Watanabe K, Itagaki I, Sakai K, Ruggeri ZM. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 1991; 87: 1234-40.
• 22 Francesconi MA, Deaha R, Girolami A, Pontara E, Casonato A. Platelet aggregation induced by plasma from type IIB von Willebrand’s disease patients is associated with an increase in cytosolic Ca²⁺ concentration. Thromb Haemost 1993; 70: 697-701.
• 23 Chow TW, Hellums JD, Moake JL, Kroll MH. Shear stress-induced von Willebrand factor binding to platelet glycoprotein-Ib initiates calcium influx associated with aggregation. Blood 1992; 80: 113-20.
• 24 Philipp DR, Charo IF, Scarborough RM. GpIIb-IIIa: the responsive integrin. Cell 1991; 65: 359-65.
• 25 Gulino D, Boudignon C, Zhang L, Concord E, Rabiet MJ, Marguerie G. Ca²⁺ binding properties of the platelet glycoprotein IIb ligand domain. J Biol Chem 1992; 267: 1001-7.
• 26 Cooney KA, Ginsburg D. Comparative analysis of type 2b von Willebrand disease mutations : implications for the mechanism of von Willebrand factor binding to platelets. Blood 1996; 87: 2322-8.
• 27 Gaucher C, de Romeuf C, Rauïs-Morret M, Corrazza F, Fondu P, Mazurier C. Diagnosis of subtype 2B von Willebrand disease in a patient with 2A phenotype of plasma von Willebrand factor. Thromb Haemost 1995; 73: 610-6.